Cytosorbents (NASDAQ:CTSO) CEO Buys $22,644.00 in Stock

Cytosorbents Corporation (NASDAQ:CTSO) CEO Phillip Chan acquired 3,774 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was purchased at an average cost of $6.00 per share, with a total value of $22,644.00. Following the transaction, the chief executive officer owned 100,996 shares of the company’s stock, valued at approximately $605,976. The trade was a 3.88% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Cytosorbents Stock Performance

Shares of CTSO opened at $5.75 on Friday. Cytosorbents Corporation has a 1 year low of $5.13 and a 1 year high of $20.40. The company’s 50 day simple moving average is $7.08 and its 200 day simple moving average is $9.68. The company has a market capitalization of $18.12 million, a price-to-earnings ratio of -0.99 and a beta of 1.34. The company has a debt-to-equity ratio of 4.70, a quick ratio of 0.50 and a current ratio of 0.66.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.73. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%. The firm had revenue of $9.63 million during the quarter, compared to analysts’ expectations of $9.38 million. On average, sell-side analysts predict that Cytosorbents Corporation will post -4.4 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a report on Monday, July 6th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $107.50.

About Cytosorbents

CytoSorbents Corporation develops medical devices and blood-purification technologies designed to remove harmful substances from the bloodstream. Its proprietary technology uses porous polymer adsorbent beads that can capture and reduce levels of inflammatory mediators, drugs, toxins and other compounds without selectively removing beneficial blood components.

The company’s principal product, CytoSorb, is used in extracorporeal blood purification applications, including the management of cytokine storms and other inflammatory conditions associated with critical illness, cardiac surgery, trauma and sepsis.